AlphaYou
Overview
Smart money at a glance
Filings to Sep 27, 2026Net selling: insiders sold $942K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$942K netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 27- Open
- $4.80
- 52-wk high
- $5.47
- High
- $4.90
- 52-wk low
- $1.95
- Low
- $4.72
- Prev close
- $4.79
- Mkt cap
- $196.8M
- P/E
- 1.1x
- Volume
- 177.9K
- Beta
- 1.19
- P/S
- 86.5x
- P/B
- 0.6x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- +74.2%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about ORMP filings
Are insiders buying or selling Oramed Pharmaceuticals Inc (ORMP) stock?
Net selling: insiders sold $942K and bought $0 of ORMP stock on the open market in the 90 days to Sep 27, 2026, according to SEC Form 4 filings. $942K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Hexter, Joshua (COO & Cbo), who sold $611K. The latest filing was on Jul 2, 2026.
Which members of Congress have traded ORMP recently?
None. No member of Congress disclosed a ORMP trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this ORMP smart-money data?
This summary uses filings available on Sep 27, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What insiders are doing
How top traders are positioned
No tracked top-trader positions in ORMP right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 120.9% below what analysts expected.
Earnings per share
$0.43 expected
Reports Nov 12, 2026, in 46 days
Financials
Is the business strong?
Fairly priced and running thin margins.
- Net margin
- 0.0%
- P/E
- 1.15
- Market cap
- $197M
Valuation
- P/S86.55
- P/B0.62
- Dividend yield0.0%
Quality
- Operating margin0.0%
- ROE74.2%
- ROA-3.4%
Growth
- Beta1.19
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace